Evidence map›Paper›PMID 31143851›Full record

ArticleBMC rheumatology2019

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS).

Gary J Macfarlane, Ejaz Pathan, Stefan Siebert, Jonathan Packham, Karl Gaffney, Ernest Choy, Raj Sengupta, Fabiola Atzeni, Kathryn R Martin, Gareth T Jones and 1 more

Abstract read
In one paragraph

Article in BMC rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gary J Macfarlane1Epidemiology Group, School of Medicine, Medical Sciences and Nutrition and The Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD UK.ORCID 0000-0003-2322-3314
Ejaz Pathan2Department of Rheumatology, Spondylitis Program, Toronto Western Hospital, University Health Network, Toronto, Ontario Canada.
Stefan Siebert3Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Jonathan Packham4Institute of Primary Care and Health Sciences, Keele University, Keele, UK.
Karl Gaffney5Department of Rheumatology, Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
Ernest Choy6CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Raj Sengupta7Royal National Hospital for Rheumatic Diseases, Bath, UK.
Fabiola Atzeni8Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.
Kathryn R Martin1Epidemiology Group, School of Medicine, Medical Sciences and Nutrition and The Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD UK.
Gareth T Jones1Epidemiology Group, School of Medicine, Medical Sciences and Nutrition and The Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD UK.
Linda E Dean1Epidemiology Group, School of Medicine, Medical Sciences and Nutrition and The Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD UK.

Funding

Versus Arthritis 21378
6 · The paper itself

Abstract

backgroundAround 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.

methodsThe British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012-2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria.

resultsOne thousand three hundred thirty-eight participants were included of whom 23% met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial (

conclusionsThe major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.

Indexed as

Axial spondyloarthritisCluster analysisComorbidityCriteriaDisease registerFibromyalgia

Identifiers

PMID31143851
PMCPMC6532149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.